Prof. Hai-Qiang Mai
✓ Available through China Expert Care
Assistant President; Director, Department of Nasopharyngeal Carcinoma; Professor and Chief Physician
Department of Nasopharyngeal Carcinoma, Sun Yat-sen University Cancer Center

Focus: Comprehensive treatment of nasopharyngeal cancer, including chemoradiotherapy and immunotherapy
Prof. Mai leads the Department of Nasopharyngeal Carcinoma at Sun Yat-sen University Cancer Center. He was the first author of JUPITER-02, the international phase III trial of toripalimab plus chemotherapy that supported the first US FDA approval of a drug for nasopharyngeal cancer.
Conditions: Nasopharyngeal cancer
Selected publications
- Nature Medicine, 2021 (first author): Toripalimab or placebo plus chemotherapy as first-line treatment in advanced nasopharyngeal carcinoma: a multicenter randomized phase 3 trial. PubMed 34341578
- JAMA, 2023 (first author): Toripalimab Plus Chemotherapy for Recurrent or Metastatic Nasopharyngeal Carcinoma: The JUPITER-02 Randomized Clinical Trial. PubMed 38015220
- Journal of the National Cancer Institute, 2011 (senior author): Concurrent chemoradiotherapy vs radiotherapy alone in stage II nasopharyngeal carcinoma: phase III randomized trial. PubMed 22056739
- Lancet Oncology, 2018 (senior author): Concurrent chemoradiotherapy with nedaplatin versus cisplatin in stage II-IVB nasopharyngeal carcinoma: an open-label, non-inferiority, randomised phase 3 trial. PubMed 29501366
Profile on the hospital website: https://english.sysucc.org.cn/info_26.aspx?itemid=456
Request a written opinion from Prof. Hai-Qiang Mai
Send your records. A medical coordinator will reply within 24 hours.
Start here